🛡️

Immunodeficiency Nursing

GCC Clinical Guide  |  Primary & Secondary Immune Disorders  |  SCFHS DHA/DOH KFSH Reference

Primary Immunodeficiency (PID) — Classification

CategoryDisorderDefectCharacteristic InfectionsKey Lab Finding
B-CellXLA (Bruton's)Absent B cells; BTK gene mutation (X-linked)Recurrent encapsulated bacteria: S. pneumoniae, H. influenzae, S. aureusAbsent immunoglobulins (all classes); absent B cells on flow
B-CellSelective IgA DeficiencyAbsent IgA; normal IgG/IgMSinopulmonary; GI (Giardia); anaphylaxis risk with blood productsIgA <0.07 g/L
T-CellDiGeorge SyndromeThymic aplasia; 22q11 deletionOpportunistic: PCP, CMV, candida; viral infectionsLow/absent T cells; hypocalcaemia; cardiac anomalies
T-CellSCIDCombined T & B cell absence (multiple genetic causes)Life-threatening opportunistic infections in infancyTREC assay (newborn screen); absent lymphocytes
CombinedCVIDMost common symptomatic PID in adults; B-cell dysfunctionRecurrent sinopulmonary (encapsulated bacteria); Giardia; enteroviral meningitisLow IgG + IgA and/or IgM; poor vaccine responses
ComplementC3 DeficiencyAbsent C3; opsonisation failureSevere/recurrent encapsulated bacteriaLow CH50; absent C3
ComplementC5–C9 Deficiency (MAC)Absent membrane attack complexNeisseria meningitidis, N. gonorrhoeae — recurrentLow CH50; absent terminal complement
PhagocyteCGD (Chronic Granulomatous Disease)NADPH oxidase defect; cannot kill catalase+ organismsS. aureus, Aspergillus, Burkholderia, Nocardia, SerratiaAbnormal DHR/NBT test; normal immunoglobulins
PhagocyteLAD (Leukocyte Adhesion Defect)CD18 deficiency; neutrophil migration failureDelayed umbilical cord separation; skin/mucosal infections without pusPersistent neutrophilia; absent CD11b/CD18 on flow

10 Warning Signs of PID (Jeffrey Modell Foundation)

  1. ≥4 new ear infections/year
  2. ≥2 serious sinus infections/year
  3. ≥2 months on antibiotics with little effect
  4. ≥2 pneumonias/year
  5. Failure to thrive in infants
  6. Recurrent deep skin/organ abscesses
  7. Persistent oral/cutaneous candidiasis >1 year
  8. Need for IV antibiotics to clear infections
  9. ≥2 deep-seated infections (meningitis/osteomyelitis/septicaemia)
  10. Family history of PID
GCC PEARL: Consanguinity (25–60% of marriages in some GCC regions) significantly increases prevalence of autosomal recessive PIDs — SCID, CGD, LAD.

Newborn Screening — TREC Assay (SCID)

TREC = T-cell receptor excision circles. Absent/low TRECs indicate absence of T-cell development.

  • Heel-prick blood spot; results in 24–48h
  • Saudi Arabia has one of the highest global SCID rates (estimated 1:20,000–1:58,000 live births) due to consanguinity
  • MOH Saudi Arabia has national newborn screening programme including SCID
  • Early identification allows curative HSCT before infections

GCC Consanguinity & PID Prevalence

  • Saudi Arabia: consanguinity rate ~56%; Qatar ~54%; Kuwait ~46%
  • Autosomal recessive PIDs disproportionately elevated: SCID, CGD, LAD, MHC class II deficiency
  • KFSH&RC Riyadh — largest PID programme in the Middle East region
  • Nurses should have lower threshold for PID suspicion in consanguineous families

Secondary Immunodeficiency (SID) — Causes & Management

HIV/AIDS — CD4 Count Thresholds for Opportunistic Infection Risk

CD4 Count (/µL)Clinical StageKey OI RisksProphylaxis Indicated
<500Symptomatic HIVOral candidiasis, TB reactivation, bacterial infectionsConsider cotrimoxazole in high-TB settings
<200AIDS-defining / PCP riskPCP, progressive multifocal leukoencephalopathy (PML), cryptosporidiosisCotrimoxazole (PCP + toxoplasmosis prophylaxis)
<100Severe AIDSToxoplasmosis, cryptococcal meningitis, CMV diseaseCotrimoxazole; check Toxo IgG
<50Very severe AIDSCMV retinitis, MAC, CNS lymphomaAzithromycin (MAC prophylaxis); ophthalmology referral

Drug-Induced Immunodeficiency

  • Corticosteroids — impair T-cell function, neutrophil migration; PCP risk if prednisone >20mg >4 weeks → cotrimoxazole prophylaxis
  • Ciclosporin / Tacrolimus — calcineurin inhibitors; T-cell suppression; CMV/EBV risk
  • MMF (Mycophenolate) — B & T cell proliferation inhibition
  • Cyclophosphamide — hypogammaglobulinaemia; prolonged neutropenia
  • Rituximab (anti-CD20) — B-cell depletion lasting 6–12 months; hypogammaglobulinaemia → IVIG replacement
  • Checkpoint inhibitors — immune dysregulation, not deficiency per se

Haematological Malignancy

  • CLL — hypogammaglobulinaemia (low IgG/IgA/IgM) → recurrent sinopulmonary infections; IVIG if <5g/L IgG with infections
  • Myeloma — suppressed normal immunoglobulins (immune paresis); encapsulated bacteria; penicillin prophylaxis; IVIG
  • Lymphoma post-CHOP — neutropenia nadir day 10–14; G-CSF; cotrimoxazole
  • Neutropenia febrile — empiric broad-spectrum antibiotics within 1 hour (piperacillin/tazobactam or cefepime); risk-stratify with MASCC/CISNE score

Post-Splenectomy (OPSS Risk)

Overwhelming Post-Splenectomy Sepsis — rapidly fatal; caused by encapsulated organisms: S. pneumoniae (most common), H. influenzae type b, N. meningitidis

  • Lifelong penicillin V prophylaxis (or amoxicillin) — especially first 2 years and children
  • Emergency standby antibiotics (amoxicillin/clavulanate) + patient education
  • Vaccination: pneumococcal (PCV13 + PPV23), MenACWY, Hib, annual influenza
  • Medical alert identification; inform healthcare workers

Other SID Causes

  • Post-BMT — early phase: neutropenia → bacterial/fungal; engraftment: CMV, Aspergillus; late: encapsulated organisms
  • Malnutrition — protein-energy malnutrition impairs T-cell, complement, mucosal immunity
  • Diabetes Mellitus — GCC context: high DM prevalence (UAE ~19%, Saudi ~18%); hyperglycaemia impairs neutrophil function, opsonisation; higher risk fungal (mucormycosis), TB, skin infections
  • Chronic renal failure — impaired lymphocyte proliferation; poor vaccine responses
  • Burns/major trauma — barrier loss; complement consumption

HIV/AIDS Nursing

Transmission Routes

  • Sexual: unprotected anal (highest risk), vaginal, oral (low); U=U — undetectable viral load = untransmittable
  • Blood: sharing needles/equipment; needlestick injury (0.3% risk); blood transfusion (screened supply near-zero risk)
  • Vertical (MTCT): pregnancy (5–10%), delivery (10–20%), breastfeeding (5–20%); ART in mother reduces to <1%
  • NOT transmitted: saliva, tears, hugging, sharing utensils, mosquitoes

HIV Testing

  • 4th-generation Ag/Ab combo — detects p24 antigen + antibodies; window period 18–45 days; gold standard
  • Point-of-care (POCT) — rapid 20-min result; used in ANC, ED, outreach
  • Opt-out testing — offered to all; patient must actively decline; increases uptake vs opt-in
  • Nucleic acid testing (NAT) — detects RNA; window period <10 days; used for acute HIV, blood donations
  • Confirm all positives with Western blot / 2nd assay

WHO Clinical Staging (1–4)

StageClinical FeaturesCD4 Typically
Stage 1Asymptomatic; persistent generalised lymphadenopathy>500/µL
Stage 2Moderate weight loss <10%; minor mucocutaneous; recurrent URTI; herpes zoster350–500/µL
Stage 3Weight loss >10%; unexplained chronic diarrhoea; oral candidiasis; pulmonary TB; severe bacterial infections200–350/µL
Stage 4 (AIDS)PCP, CMV, toxoplasmosis, cryptococcal meningitis, Kaposi sarcoma, HIV wasting, HIV encephalopathy<200/µL

Antiretroviral Therapy (ART)

Preferred First-Line Regimen (WHO 2024)

TDF + FTC + DTG (tenofovir disoproxil fumarate / emtricitabine / dolutegravir)

  • TAF/FTC (Descovy) + DTG = preferred where renal/bone concerns
  • High barrier to resistance with INSTIs (dolutegravir, bictegravir)
  • Goal: viral load <50 copies/mL (undetectable) within 6 months

ART Class Reference

  • NRTI: TDF, TAF, FTC, 3TC, ABC, AZT
  • INSTI: DTG, BIC, RAL, EVG (preferred class)
  • NNRTI: EFV, RPV, DOR (avoid in pregnancy: EFV)
  • PI: DRV/r, LPV/r (boosted with ritonavir/cobicistat)
  • PK enhancers: ritonavir (RTV), cobicistat (COBI)

PrEP (Pre-Exposure Prophylaxis)

  • TDF/FTC daily — >99% effective if adherent; for MSM, serodiscordant couples, sex workers
  • Alternative: TAF/FTC (better renal/bone profile); injectable CAB-LA q8 weeks
  • Requires HIV-negative confirmation before starting; monitor creatinine at 3 months
  • GCC availability: UAE and Saudi Arabia have limited formal PrEP programmes; criminalisation of risk behaviours creates access barriers

nPEP (Post-Exposure Prophylaxis)

  • Must start within 72 hours (ideally <4h); 28-day course
  • Preferred regimen: TDF/FTC + DTG (or RAL)
  • Occupational PEP: report to OH immediately; baseline HIV/HBV/HCV testing; document exposure
  • Assess exposure risk: HIV status of source; viral load; type of exposure
  • Follow-up HIV testing at 6 weeks, 3 months post-exposure
ART Adherence Counselling Guide
Adherence >95% is essential. Missing >1 dose/month risks viral rebound and resistance development.
1
Assess readiness & barriers: Ask open-ended questions about daily routine, work shifts, travel, side effects, stigma, mental health, substance use, family support
2
Educate on mechanism: Explain why consistent dosing maintains viral suppression; link U=U — undetectable = untransmittable (reduces stigma-related motivation barrier)
3
Practical strategies: Pillbox; phone alarm; link to daily habit (toothbrushing); private discreet pill storage if stigma concern; pill pouches for travel
4
Side effect management: TDF — renal monitoring; DTG — insomnia/neuropsychiatric (take in morning); EFV — vivid dreams/dizziness (take at bedtime, usually resolves 2–4 weeks)
5
GCC-specific considerations: Ramadan fasting — discuss dose timing with prescriber; prayer schedule alignment; avoiding disclosure to family/employer; expatriate documentation concerns
6
Missed dose: Take as soon as remembered UNLESS near next dose time (within <12h for once-daily) — skip missed; never double-dose
7
Monitoring: Viral load at 3–6 months; CD4 6-monthly until stable; LFTs, renal function, FBC at baseline and 3 months
8
Resistance counselling: Explain that partial adherence is worse than stopping — drug-resistance mutations can permanently limit future options

Opportunistic Infections (OIs) in Immunocompromised Patients

PCP — Pneumocystis jirovecii Pneumonia

Risk: CD4 <200/µL; corticosteroids >20mg >4 weeks; post-transplant

Clinical Features

  • Subacute onset: progressive dyspnoea, dry cough, low-grade fever
  • SpO2 drop on exertion (desaturation on 6-minute walk)
  • Bilateral perihilar "ground-glass" infiltrates on CXR/CT
  • Elevated LDH (>500 IU/L — marker of severity)
  • SpO2 <70mmHg PaO2 → severe; add adjunctive corticosteroids

Treatment & Prophylaxis

  • Treatment: High-dose cotrimoxazole (TMP-SMX) 15–20mg/kg/day TMP component × 21 days
  • Severe PCP (PaO2 <70mmHg): add prednisolone 40mg BD × 5 days, then taper
  • Prophylaxis: Cotrimoxazole 960mg OD or 480mg BD (CD4 <200; start when CD4 rises >200 on ART × 3 months)
  • Alternatives if sulfa allergy: dapsone, atovaquone, inhaled pentamidine
  • Nursing: O2 therapy; monitor SpO2; strict isolation not required (droplet precautions)

CMV Retinitis

CD4 <50/µL

  • Symptoms: Floaters, scotoma (blind spot), peripheral field loss ("curtain"), decreased visual acuity — painless
  • Diagnosis: Fundoscopy — "pizza-pie" haemorrhage and exudate
  • Treatment: Valganciclovir 900mg BD (induction 21 days) → 900mg OD (maintenance)
  • Alternative: IV ganciclovir for severe/CNS disease
  • Monitoring: FBC weekly — ganciclovir causes myelosuppression (neutropenia, thrombocytopenia)
  • Nursing: Urgent ophthalmology referral; educate patient to report any visual change immediately

MAC — Mycobacterium avium Complex

CD4 <50/µL

  • Symptoms: Weight loss, fever, night sweats, profound anaemia, diarrhoea, hepatosplenomegaly
  • Diagnosis: Blood culture (mycobacterial); bone marrow biopsy; elevated ALP
  • Treatment: Clarithromycin + ethambutol ± rifabutin
  • Prophylaxis: Azithromycin 1200mg weekly (CD4 <50); stop when CD4 >100 on ART × 3 months
  • Rifabutin: significant CYP3A4 drug interactions with ART (reduce dose with PIs)

Cerebral Toxoplasmosis

CD4 <100/µL

  • Aetiology: Toxoplasma gondii reactivation; seropositive ~60% in some GCC populations (cat/raw meat exposure)
  • Symptoms: Headache, fever, focal neurological deficit, seizures, altered consciousness
  • Imaging: MRI — ring-enhancing lesions (often multiple, basal ganglia/cortex)
  • Empirical treatment: Pyrimethamine + sulfadiazine + folinic acid × 6 weeks
  • Alternative: Cotrimoxazole (treatment dose)
  • Prophylaxis: Cotrimoxazole (same as PCP prophylaxis — dual benefit)

Cryptococcal Meningitis

CD4 <100/µL

  • Aetiology: Cryptococcus neoformans (yeast; acquired by inhalation)
  • Symptoms: Subacute headache, fever, neck stiffness (may be absent), photophobia, altered consciousness; raised ICP
  • Diagnosis: LP — India ink, cryptococcal antigen (CrAg); serum CrAg screen
  • Treatment: Amphotericin B + flucytosine (induction 2 weeks) → fluconazole consolidation/maintenance
  • Nursing: ICP management (therapeutic LPs); strict input/output; amphotericin — nephrotoxicity, hypokalaemia, rigors (pre-medicate: paracetamol + hydrocortisone)

Oral & Oesophageal Candidiasis

Oral (thrush): CD4 <300; white plaques (scrape off leaving erythema); treat with fluconazole 100–200mg × 7–14 days or nystatin suspension

Oesophageal (AIDS-defining): dysphagia, odynophagia; treat empirically with fluconazole 200mg × 14–21 days; endoscopy if no response; step-up to itraconazole or caspofungin

Immunoglobulin Replacement Therapy

Indications

Primary ID

  • XLA (Bruton's)
  • CVID
  • SCID (bridge to HSCT)
  • Hypogammaglobulinaemia NOS

Secondary ID

  • Post-rituximab hypogammaglobulinaemia
  • CLL with IgG <5g/L + recurrent infections
  • Myeloma with immune paresis + infections
  • Post-BMT (until immune reconstitution)

Non-ID Indications

  • ITP (high-dose IVIG)
  • Kawasaki disease
  • GBS / CIDP
  • Myasthenia gravis crisis
IVIG Infusion Rate Titration Protocol
CRITICAL: Always check IgA level before first infusion. IgA-deficient patients risk anaphylaxis with IgA-containing IVIG products. Use IgA-depleted product (e.g. Privigen) if IgA <0.07g/L.

Pre-Infusion Checklist

  • FBC, renal function (baseline eGFR — IVIG can cause osmotic nephropathy with sucrose-stabilised products)
  • IgA level — critical before first infusion
  • Confirm dose (typically 400–600mg/kg q3–4 weeks for replacement); batch number documentation
  • Premedication if previous reactions: paracetamol 1g + chlorphenamine 10mg IV 30 min before
  • IV access; ensure blood glucose normal (sucrose-containing products affect BM readings)
  • Anaphylaxis kit at bedside (adrenaline 0.5mg IM, antihistamine, hydrocortisone, O2)

Rate Titration (Standard Product)

PeriodRateDurationAction if Tolerated
0–15 min0.5 mL/kg/h15 minIncrease to next rate
15–30 min1 mL/kg/h15 minIncrease to next rate
30–60 min2 mL/kg/h30 minIncrease to next rate
60 min +Up to 4–6 mL/kg/hRemainderMax rate per product SPC

Monitoring Frequency

  • Vital signs: before, at 15 min, 30 min, then every 30 min throughout infusion
  • First infusion: stay with patient for first 30 min; have resuscitation equipment nearby
  • Post-infusion observation: minimum 30–60 min

Adverse Reactions & Management

ReactionTimingManagement
Headache, flushing, rigorsDuring infusionSlow rate by 50%; paracetamol; usually resolves
UrticariaDuring/afterSlow/stop; chlorphenamine IV; restart at lower rate
Anaphylaxis (IgA-deficient)Within minutesSTOP; adrenaline 0.5mg IM lateral thigh; O2; IV fluids; call team
Haemolysis24–48h postFBC; check blood group; report to haemovigilance
Aseptic meningitis24–72h postHeadache/meningism; CT/LP to exclude infective; NSAID; usually self-limiting
Thrombosis (IVIG-associated)24–72h postRisk factors: high-dose, elderly, hyperviscosity, immobility; low-rate infusion; hydration

Subcutaneous Immunoglobulin (SCIG)

  • Weekly/bi-weekly self-infusion at home; smaller volumes → fewer systemic reactions
  • FSCIG (Facilitated SCIG — HyQvia): recombinant hyaluronidase allows single monthly infusion
  • Abdominal, thigh, upper arm sites — rotate; 2–4 infusion sites simultaneously
  • Patient training programme: 3–6 supervised infusions before home therapy
  • Local reactions (redness, swelling) common initially — usually resolve in weeks
  • Nurse-led home visit programme; 24h helpline access

IgG Monitoring & Targets

  • Check trough IgG (immediately before next infusion) every 3–6 months
  • Target: >7g/L for most PID (XLA/CVID)
  • Higher target (>8–10g/L) if still having breakthrough infections
  • Increase dose/frequency if trough below target despite adherence
  • Document: batch number, lot number, manufacturer, expiry for all blood product traceability
  • Annual review: clinical response, infection frequency, quality of life (SF-36)

GCC Context & Exam Preparation

PID in GCC

  • Consanguinity: Saudi Arabia ~56%; UAE ~40%; Qatar ~54% — autosomal recessive PIDs significantly elevated
  • Saudi SCID rate: estimated 1:20,000–1:58,000 live births (among world's highest)
  • KFSH&RC Riyadh: largest PID programme in Middle East; pioneered HSCT for SCID in region
  • Saudi national newborn screening: includes SCID (TREC assay), MSUD, PKU, congenital hypothyroidism
  • CGD, LAD, MHC class II deficiency (bare lymphocyte syndrome) also elevated in GCC vs Western populations
  • Nurses should document family history of consanguinity and childhood deaths (possible undiagnosed PID)

HIV in GCC — Special Considerations

  • HIV criminalised in most GCC states; mandatory testing for certain visas/employment
  • Deportation risk for HIV-positive expatriates → significant barrier to testing and disclosure
  • Underreporting: official rates low but likely underestimated due to criminalisation
  • Late presentation common (lower CD4 at diagnosis)
  • Healthcare worker obligations: Confidentiality vs. legal reporting requirements vary by country; know local MOH regulations
  • Saudi MOH 2022: ART provided free at HAAD/DHA-designated centres; anonymous testing available at some clinics
  • Stigma reduction: PLHIV-centred language; avoid "AIDS patient" — use "person living with HIV"

SCFHS & DHA/DOH Nursing Competencies

  • SCFHS immunology competencies: infection risk assessment, isolation precautions, medication administration (IVIG, ART), patient education, reporting
  • DHA (Dubai Health Authority) competency framework: immunocompromised patient care in Level III hospitals
  • DOH (Abu Dhabi Department of Health): Immunology nursing scope includes home SCIG oversight
  • All GCC nurses: mandatory training in standard/transmission-based precautions; PPE donning/doffing competency
Post-Splenectomy Vaccination & Prophylaxis Schedule
Ideally vaccinate 2 weeks BEFORE elective splenectomy. If emergency: vaccinate at 2 weeks post-op (once immune response recoverable).
VaccineScheduleBooster
PCV13 (Prevenar)1 dose pre/post-opThen PPV23 at 8 weeks after PCV13
PPV23 (Pneumovax)8 weeks after PCV13Every 5 years
MenACWY1 doseEvery 5 years (or MenB 2-dose for extra coverage)
Hib (if not previously vaccinated)1 doseSingle dose sufficient for adults
InfluenzaAnnualAnnual

Antibiotic Prophylaxis

  • Phenoxymethylpenicillin (Pen V) 250mg–500mg BD — lifelong (especially first 2 years)
  • If penicillin allergy: erythromycin 250mg BD
  • Children: prophylaxis until at least age 16 (some guidelines: lifelong)
  • Emergency supply: amoxicillin 3g single dose (or co-amoxiclav 3g) — patient holds supply; take at first sign of fever and seek emergency care
  • Medical alert card/bracelet: "I have no spleen — risk of life-threatening infection"

Immunocompromised Patient Infection Risk Assessment Tool


GCC Exam Preparation — 5 MCQs

Q1. A 6-month-old Saudi male presents with recurrent Staphylococcus aureus and Aspergillus infections. Flow cytometry shows normal lymphocyte counts. The dihydrorhodamine (DHR) test is abnormal. What is the most likely diagnosis?
CGD is a phagocyte disorder caused by NADPH oxidase deficiency. Catalase-positive organisms (S. aureus, Aspergillus, Nocardia, Serratia) are characteristically affected. The DHR/NBT test is the diagnostic test of choice — absent oxidative burst confirms CGD. Normal lymphocyte counts rule out B- and T-cell disorders. CGD is more prevalent in GCC due to consanguinity.
Q2. An HIV-positive patient with a CD4 count of 45/µL reports 3 days of painless visual floaters and a "curtain" over the left eye. Which is the MOST appropriate initial nursing action?
CD4 <50 + painless floaters + field loss = CMV retinitis until proven otherwise. This is sight-threatening — retinal detachment can occur within days. Same-day ophthalmology is mandatory. Treatment is valganciclovir. Fluconazole is for candida, not CMV. Delay risks permanent vision loss.
Q3. You are preparing to administer IVIG to a patient with CVID. Pre-infusion IgA level returns as undetectable (<0.07 g/L). What is the MOST important action before proceeding?
IgA-deficient patients can have anti-IgA antibodies and develop severe anaphylaxis if given IgA-containing IVIG products. The correct response is to use an IgA-depleted product (e.g., Privigen, Octagam 10%). Anaphylaxis kit must be immediately available. Simply slowing the infusion rate does not prevent IgA-mediated anaphylaxis.
Q4. A 35-year-old woman 3 months post-splenectomy for traumatic rupture presents to the ED with fever 39.2°C, rigors and hypotension. She reports she was "not given vaccines after her operation." What is the PRIORITY management step?
This is Overwhelming Post-Splenectomy Sepsis (OPSS) — a life-threatening emergency with mortality up to 50–70%. Encapsulated organisms (S. pneumoniae most common) cause fulminant sepsis. Blood cultures must be taken but antibiotics must NOT be delayed awaiting results. IV cephalosporin (ceftriaxone 2g IV) must be given within 30 minutes. Vaccination can follow once the patient is stabilised.
Q5. An HIV-positive patient on TDF/FTC/DTG has been virologically suppressed (VL <50 copies/mL) for 18 months. He asks whether he can have unprotected sex with his HIV-negative partner. Which statement best reflects current evidence?
U=U (Undetectable = Untransmittable) is supported by the PARTNER1, PARTNER2, and Opposites Attract studies — zero transmissions occurred from virologically suppressed HIV-positive individuals. This applies to both heterosexual and MSM couples. This is a key counselling point that also reduces HIV stigma. Condoms are still recommended for STI prevention, but the patient should be counselled that sexual HIV transmission risk is effectively zero with sustained viral suppression.